When is proton pump inhibitor use appropriate?

被引:60
作者
Yadlapati, Rena [1 ]
Kahrilas, Peter J. [1 ,2 ]
机构
[1] Northwestern Univ, Dept Med, Feinberg Sch Med, Chicago, IL 60611 USA
[2] Northwestern Univ, Dept Med, Feinberg Sch Med, Div Gastroenterol & Hepatol, 676 N St Clair St,14th Floor, Chicago, IL 60611 USA
来源
BMC MEDICINE | 2017年 / 15卷
关键词
Proton pump inhibitors; Gastroesophageal reflux disease; Indication; RISK; POPULATION; DISEASES; THERAPY;
D O I
10.1186/s12916-017-0804-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Proton pump inhibitor (PPI) therapy is commonly used outside of Food and Drug Administration indication for a broad range of conditions such as extra-esophageal reflux and PPI-responsive esophageal eosinophilia. While this may be appropriate in some scenarios, it has also resulted in widespread inappropriate PPI use. At the same time, data suggesting adverse effects of long-term PPI therapy are multiplying, albeit mainly from low quality studies. The systematic review by Scarpignato et al. (BMC Med 14:179, 2016) addresses this dilemma with a comprehensive analysis of the risks and benefits of PPI use. The authors concluded that, while PPIs are highly efficacious in erosive acid-peptic disorders, efficacy is not equaled in other conditions. In some instances, they found no supportive evidence of benefit. With respect to side effects, they indicated that the questionable harms associated with PPI therapy do not outweigh the benefits afforded by appropriate PPI use. However, inappropriate PPI use results in increased healthcare costs and unnecessary exposure to potential adverse effects. Ideally, PPI therapy should be personalized, based on indication, effectiveness, patient preference, and risk assessment.
引用
收藏
页数:4
相关论文
共 14 条
[1]   Burden of Digestive Diseases in the United States Part I: Overall and Upper Gastrointestinal Diseases [J].
Everhart, James E. ;
Ruhl, Constance E. .
GASTROENTEROLOGY, 2009, 136 (02) :376-386
[2]   Just How "Difficult" Is It to Withdraw PPI Treatment? [J].
Howden, Colin W. ;
Kahrilas, Peter J. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 (07) :1538-1540
[3]   Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy [J].
Jalving, M. ;
Koornstra, J. J. ;
Wesseling, J. ;
Boezen, H. M. ;
De Jong, S. ;
Kleibeuker, J. H. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 24 (09) :1341-1348
[4]   Risks associated with chronic PPI use - signal or noise? [J].
Kia, Leiila ;
Kahrilas, Peter J. .
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2016, 13 (05) :253-U15
[5]   Proton Pump Inhibitors and Hypomagnesemia in the General Population: A Population-Based Cohort Study [J].
Kieboom, Brenda C. T. ;
Kiefte-de Jong, Jessica C. ;
Eijgelsheim, Mark ;
Franco, Oscar H. ;
Kuipers, Ernst J. ;
Hofman, Albert ;
Zietse, Robert ;
Stricker, Bruno H. ;
Hoorn, Ewout J. .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2015, 66 (05) :775-782
[6]   Proton Pump Inhibitor and Histamine-2 Receptor Antagonist Use and Iron Deficiency [J].
Lam, Jameson R. ;
Schneider, Jennifer L. ;
Quesenberry, Charles P. ;
Corley, Douglas A. .
GASTROENTEROLOGY, 2017, 152 (04) :821-+
[7]   Proton Pump Inhibitor and Histamine 2 Receptor Antagonist Use and Vitamin B12 Deficiency [J].
Lam, Jameson R. ;
Schneider, Jennifer L. ;
Zhao, Wei ;
Corley, Douglas A. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 310 (22) :2435-2442
[8]   Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease [J].
Lazarus, Benjamin ;
Chen, Yuan ;
Wilson, Francis P. ;
Sang, Yingying ;
Chang, Alex R. ;
Coresh, Josef ;
Grams, Morgan E. .
JAMA INTERNAL MEDICINE, 2016, 176 (02) :238-246
[9]   Proton Pump Inhibitor Use and the Risk of Small Intestinal Bacterial Overgrowth: A Meta-analysis [J].
Lo, Wai-Kit ;
Chan, Walter W. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2013, 11 (05) :483-490
[10]   Extra-esophageal manifestations of gerd: Who responds to GERD therapy? [J].
Naik R.D. ;
Vaezi M.F. .
Current Gastroenterology Reports, 2013, 15 (4)